BioCentury | Feb 4, 2021
Deals

Feb. 3 Quick Takes: Hillhouse takes stakes in InnoCare, Luye; plus Merck KGaA, Inivata, Reverie, Neurocrine, Eisai and more

...BioLabs launch neuro-focused incubator in CambridgeA U.S. subsidiary of Eisai Co. Ltd. (Tokyo:4523) partnered with BioLabs Inc....
BioCentury | Oct 6, 2020
Product Development

Industry research contributes to Nobel Prize for HCV discovery

...In 1993, Richard Roberts of New England Biolabs Inc....
BioCentury | Apr 26, 2019
Financial News

Nanjing Leads closes series A for immuno-oncology programs

...Phase I trial of LBL-007 in China in 3Q19. The company’s fully owned subsidiary Leads Biolabs Inc....
BioCentury | Dec 7, 2018
Tools & Techniques

Germline editing gets technical

...Macrogen Inc. (KOSDAQ:038290) Seoul, South Korea Mission Bio Inc. South San Francisco, Calif. New England Biolabs Inc....
BioCentury | Mar 7, 2018
Distillery Therapeutics

Cancer

...include testing the combination of FACT inhibition and chemotherapy in additional models of SCLC. Cleveland BioLabs Inc....
BioCentury | Feb 8, 2016
Clinical News

Entolimod: Phase II started

...5 days before surgery with or without a second injection 3 days before surgery. Cleveland BioLabs Inc....
BioCentury | Feb 1, 2016
Clinical News

CBLB612: Phase II started

...cancer patients. The study is supported by a development contract with the Russian government. Cleveland BioLabs Inc....
BioCentury | Nov 9, 2015
Financial News

Cleveland BioLabs withdraws follow-on

...Cleveland BioLabs Inc. (NASDAQ:CBLI), Buffalo, N.Y. Business: Cancer, Other, Hematology Date announced: 2015-11-04 Type: Follow-on Underwriter: Ladenburg...
BioCentury | Jul 20, 2015
Clinical News

Protectan CBLB612: Phase I data

...to dose-dependent increases in circulating absolute neutrophil counts that lasted for about 20 hours. Cleveland BioLabs Inc....
BioCentury | Jul 16, 2015
Distillery Therapeutics

Therapeutics: Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL); nuclear factor of κ light polypeptide gene enhancer in B cells 1 (NF-κB; NF

...indirectly inhibit NF-κB in Phase I testing to treat non-small cell lung cancer (NSCLC). Cleveland BioLabs Inc....
Items per page:
1 - 10 of 129
BioCentury | Feb 4, 2021
Deals

Feb. 3 Quick Takes: Hillhouse takes stakes in InnoCare, Luye; plus Merck KGaA, Inivata, Reverie, Neurocrine, Eisai and more

...BioLabs launch neuro-focused incubator in CambridgeA U.S. subsidiary of Eisai Co. Ltd. (Tokyo:4523) partnered with BioLabs Inc....
BioCentury | Oct 6, 2020
Product Development

Industry research contributes to Nobel Prize for HCV discovery

...In 1993, Richard Roberts of New England Biolabs Inc....
BioCentury | Apr 26, 2019
Financial News

Nanjing Leads closes series A for immuno-oncology programs

...Phase I trial of LBL-007 in China in 3Q19. The company’s fully owned subsidiary Leads Biolabs Inc....
BioCentury | Dec 7, 2018
Tools & Techniques

Germline editing gets technical

...Macrogen Inc. (KOSDAQ:038290) Seoul, South Korea Mission Bio Inc. South San Francisco, Calif. New England Biolabs Inc....
BioCentury | Mar 7, 2018
Distillery Therapeutics

Cancer

...include testing the combination of FACT inhibition and chemotherapy in additional models of SCLC. Cleveland BioLabs Inc....
BioCentury | Feb 8, 2016
Clinical News

Entolimod: Phase II started

...5 days before surgery with or without a second injection 3 days before surgery. Cleveland BioLabs Inc....
BioCentury | Feb 1, 2016
Clinical News

CBLB612: Phase II started

...cancer patients. The study is supported by a development contract with the Russian government. Cleveland BioLabs Inc....
BioCentury | Nov 9, 2015
Financial News

Cleveland BioLabs withdraws follow-on

...Cleveland BioLabs Inc. (NASDAQ:CBLI), Buffalo, N.Y. Business: Cancer, Other, Hematology Date announced: 2015-11-04 Type: Follow-on Underwriter: Ladenburg...
BioCentury | Jul 20, 2015
Clinical News

Protectan CBLB612: Phase I data

...to dose-dependent increases in circulating absolute neutrophil counts that lasted for about 20 hours. Cleveland BioLabs Inc....
BioCentury | Jul 16, 2015
Distillery Therapeutics

Therapeutics: Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL); nuclear factor of κ light polypeptide gene enhancer in B cells 1 (NF-κB; NF

...indirectly inhibit NF-κB in Phase I testing to treat non-small cell lung cancer (NSCLC). Cleveland BioLabs Inc....
Items per page:
1 - 10 of 129